Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 25 - Drugs for disorders of the nervous system
Patents for A61P 25 - Drugs for disorders of the nervous system (183,225)
10/2002
10/31/2002WO2002085887A1 Phenyl- and pyridyl-piperidines with tnf activity
10/31/2002WO2002085871A2 Serotonergic agents with long-acting in vivo effects
10/31/2002WO2002085866A1 Novel compounds
10/31/2002WO2002085863A1 Novel compounds of the family of 3-alkyl-(4,5 diphenyl-imidazol-1-yl) and their use as soothing agents
10/31/2002WO2002085859A1 HETEROARYL UREAS CONTAINING NITROGEN HETERO-ATOMS AS p38 KINASE INHIBITORS
10/31/2002WO2002085856A1 Synthesis and methods of use of tetrahydroindolone analogues and derivatives
10/31/2002WO2002085855A1 2-iminopyrrolidine derivatives
10/31/2002WO2002085853A2 Heterocyclylalkoxy-, -alkylthio- and -alkylaminobenzazole derivatives as 5-hydroxytryptamine-6 ligands
10/31/2002WO2002085850A1 Cyclic amidine derivative
10/31/2002WO2002085843A2 Process for the preparation of 1,3-substituted indenes and aryl-fused azapolycyclic compounds
10/31/2002WO2002085839A1 Fused bicyclic or tricyclic amino acids
10/31/2002WO2002085414A2 Nsaid formulations comprising lecithin oils for protecting the gastrointestinal tract and providing enhanced therapeutic activity
10/31/2002WO2002085402A1 Methods and compositions for treating oral and eosophageal lesions
10/31/2002WO2002085392A1 Method for using puerariae radix, puerariae radix flavone extract and preparation containing puerarin in the prevention and treatment of new indications
10/31/2002WO2002085370A1 Utilization of galanthamine for the treatment of pathologies of the central nervous system owing to intoxications with psychotropic substances
10/31/2002WO2002085368A2 Use of radical scavenging compounds for treatment and prevention of no-dependent microcirculation disorders
10/31/2002WO2002085366A1 Aripiprazole oral solution
10/31/2002WO2002085361A1 Benzimidazolone compounds
10/31/2002WO2002085357A1 Nociceptin analogs
10/31/2002WO2002085355A1 Spiropyrazole compounds
10/31/2002WO2002085354A1 Spiroindene and spiroindane compounds
10/31/2002WO2002085346A1 Use of creatine for the amelioration of oxidative stress
10/31/2002WO2002085341A2 Composition, containing carnitine and huperzin for the preventionor treatment of learning disorders in children suffering from attention deficit/hyperactive disorder
10/31/2002WO2002085336A1 Orodispersible effervescent tablets
10/31/2002WO2002085330A1 Biofunctional hydroxyapatite coatings and microspheres for in-situ drug encapsulation
10/31/2002WO2002085293A2 Production of alpha-lipoic acid
10/31/2002WO2002085291A2 Nociceptin analogs
10/31/2002WO2002085268A1 Disposal system for transdermal dosage form
10/31/2002WO2002069895A3 Heterocyclic analgesic compounds and methods of use thereof
10/31/2002WO2002068381A3 Aryl-n-cyanoguanidines and methods related thereto
10/31/2002WO2002066681A9 Reagents and methods for identifying and modulating expression of genes regulated by cdk inhibitors
10/31/2002WO2002061105A9 Chimeric molecules containing a module able to target specific cells and a module regulating the apoptogenic function of the permeability transition pore complex (ptpc)
10/31/2002WO2002056892A3 Methods of treating neurological disorders
10/31/2002WO2002054066A3 Non-apoptotic forms of cell death and methods of modulation
10/31/2002WO2002051428A8 Sympathetic-activating perfume composition
10/31/2002WO2002048105A3 Aryloxy piperidinyl derivatives for the treatment of depression
10/31/2002WO2002042455A3 Modifier of organelle metalbolism
10/31/2002WO2002036105A3 Use of cortisol-sequestering agents for the treatment of hypercortisolaemia related disorders
10/31/2002WO2002033080A3 Regulation of human netrin binding membrane receptor unc5h-1
10/31/2002WO2002022611A3 Caspase inhibitors and uses thereof
10/31/2002WO2002004002A3 Use of strains of the parapox ovis virus for producing antiviral pharmaceuticals and anticancer pharmaceuticals
10/31/2002WO2001093896A3 A method of treatment of alzheimer's disease with a protein extractable from mammalian organs
10/31/2002WO2001093895A3 A method of treatment of huntington's chorea with a protein extractable from mammalian organs
10/31/2002WO2001093894A3 A method of treatment of parkinson's disease with a protein extractable from mammalian organs
10/31/2002WO2001058479A9 Immunotherapy using interleukin 13 receptor subunit alpha 2
10/31/2002WO2001055432A3 Polymorphisms in the human cyp2d6 gene promoter region and their use in diagnostic and therapeutic applications
10/31/2002WO2001044243A3 Novel heteroaryl-diazabicycloalkanes
10/31/2002WO2000062766A3 Uses of ppar-gamma agonists in neutrophil-induced diseases
10/31/2002US20020162130 Transgenic mouse expressing the human cyclooxygenase-2 gene and neuronal cell cultures derived therefrom
10/31/2002US20020162129 Prevention and treatment of alzheimer's disease
10/31/2002US20020161262 Use treating various medical conditions, including pain
10/31/2002US20020161228 Piperidine compounds
10/31/2002US20020161222 Hydrogenation of 5,5-dioxo-2,3-dihydro-1H-pyrrolo-(2,1-c)(1,2,4)benzothiadiazine with a complex of ruthenium dichloride with 2,2'-bis(diphenylphosphine)-1,1'-binaphthyl and 1,2-diphenylethylenediamine as catalyst
10/31/2002US20020161197 Defibrinating whole blood including red blood cells and a plasma component; filtering whole blood, whereby at least a portion of plasma is separated from red blood cells to form a red blood cell suspension, thereby purifying red blood cells
10/31/2002US20020161191 Novel Imidazoline receptor homologs
10/31/2002US20020161042 Nitric oxide donor composition and method for treatment of anal disorders
10/31/2002US20020161038 Inosine 5'-monophosphate dehydrogenase (IMPDH); prodrug having functional group -CO-N(-R)-COO-, a carrier, and an immunosuppressant, anticancer agent, antiviral agent, or anti-vascular hyperproliferation agent
10/31/2002US20020161033 Substituted 1,5-dihydropyrrol-2-one derivatives active as NMDA receptor antagonists for treatment of states of pain
10/31/2002US20020161019 For treatment of depression, anxiety, feeding disorders, headache, drug addiction, inflammatory disorders
10/31/2002US20020161014 Purinyl substituted quinazoline-4-one derivatives
10/31/2002US20020161008 Agonists, antagonists or inverse agonists for GABAA brain receptors; useful in diagnosis and treatment of anxiety, depression
10/31/2002US20020161006 1,4-dihydropyridine compounds as bradykinin antagonists
10/31/2002US20020161002 Use of catecholamine reuptake inhibitors to enhance memory
10/31/2002US20020160999 Treatment of diseases or disorders of the central nervous system
10/31/2002US20020160997 Novel indole derivatives
10/31/2002US20020160996 Benzofuran substituted by a fused nitrogen-containing heterocyclic ring such as isoindoline; inhibits cytotoxicity of beta-amyloid; Alzheimer's or Parkinson's disease
10/31/2002US20020160991 Orally-bioavailable formulations of fentanyl and congeners thereof
10/31/2002US20020160988 Compounds co-inducing cholinergic up-regulation and inflammation down-regulation and uses thereof
10/31/2002US20020160984 For example, 2,3-dihydro-1H-benz(de)isoquinolin-1-one; treating diabetes, cancer, radiosensitizing tumor cells, cardiovascular disorders, septic shock, inflammatory bowel disease, senescent cells
10/31/2002US20020160982 Modafinil compound and cyclodextrin mixtures
10/31/2002US20020160974 Methods for treating autoimmune diseases in a subject and in vitro diagnostic assays
10/31/2002US20020160963 Aminomethyl-pyrroloquinazoline compounds as thrombin receptor antagonists
10/31/2002US20020160940 Modulation of endogenous gene expression in cells
10/31/2002US20020160933 Methods and compositions for producing a neurosalutary effect in a subject
10/31/2002US20020160499 For use in diagnosis, prophylaxis, and therapy of disorders associated with expression of serine carboxypeptidase
10/31/2002US20020160493 Serine/threonine phosphatase polynucleotides, polypeptides, and antibodies
10/31/2002US20020160481 Isolated human dehydrogenases, nucleic acid molecules encoding these human dehydrogenases, and uses thereof
10/31/2002US20020160478 Short peptides which selectively modulate the activity of protein kinases
10/31/2002US20020160043 Dissolvable drug-containing dosage form for use in transmucosal delivery of drug to patient, comprising binding agent formed into solid matrix dissolvable in mouth, pharmacologically effective dosage of drug, buffer
10/31/2002US20020160000 PD-1, a receptor for B7-4, and uses therefor
10/31/2002US20020159991 Modulation of Abeta levels by beta-secretase BACE2
10/31/2002US20020159976 An isolated polynucleotide comprising a nucleotide sequence present in Lactobacillus rhamnosus strain HN001 that encodes a polypeptide having atleast one enzymetic activity; genetic engineering
10/31/2002US20020159973 Administering to the patient at least one statin (HMG-Coa-reductase inhibitor) in an amount effective to modulate MHC class II (Major Histocompability complex) or CD/40(antigen) expression in the patient
10/31/2002US20020159956 Providing a chewing gum, includes a gum center and a coating coverings, coating includes a drug designed to be delivered into systemic system of indivisual
10/31/2002DE10217066A1 Composition useful for treatment of central nervous system disorders, e.g. Alzheimer's disease comprises modulator of neuron-specific calcium sensor-1
10/31/2002DE10121217A1 6H-Oxazolo[4,5-e]indol-Derivate als nikotinische Acetylcholinrezeptor Liganden und/oder serotonerge Liganden 6H-oxazolo [4,5-e] indole derivatives as nicotinic acetylcholine receptor ligands and / or serotonergic ligands
10/31/2002DE10121215A1 Dihydro-imidazo[4,5-e]indol- und 7H-Pyrrolo[3,2-f]chinoxalin Derivate als nikotinische Acetylcholinrezeptor Liganden und/oder serotonerge Liganden Dihydro-imidazo [4,5-e] indole and 7H-pyrrolo [3,2-f] quinoxaline derivatives as nicotinic acetylcholine receptor ligands and / or serotonergic ligands
10/31/2002CA2843001A1 Progenitor cell populations, expansion thereof, and growth of non-hematopoietic cell types and tissues therefrom
10/31/2002CA2445255A1 Vhh single heavy chain antibody and a method for its preparation in a mammal
10/31/2002CA2445233A1 Phthalazinones derivatives useful as pde4/7 inhibitors
10/31/2002CA2445197A1 T1r3 a novel taste receptor
10/31/2002CA2444959A1 Progenitor cell populations, expansion thereof, and growth of non-hematopoietic cell types and tissues therefrom
10/31/2002CA2444885A1 Methods and compositions for treating oral and esophageal lesions
10/31/2002CA2444675A1 Secreted proteins
10/31/2002CA2444595A1 Benzimidazolone derivatives
10/31/2002CA2444381A1 Novel compounds
10/31/2002CA2444370A1 Use of radical scavenging compounds for treatment and prevention of no-dependent microcirculation disorders
10/31/2002CA2444235A1 New polynucleotides and polypeptides of the ifn.alpha.-17 gene
10/31/2002CA2444214A1 Amyloid plaque aggregation inhibitors and diagnostic imaging agents
10/31/2002CA2444095A1 Heterocyclyloxy-, -thioxy- and -aminobenzazole derivatives as 5-hydroxytryptamine-6 ligands
1 ... 1284 1285 1286 1287 1288 1289 1290 1291 1292 1293 1294 1295 1296 1297 1298 1299 1300 1301 1302 1303 1304 ... 1833